4//SEC Filing
Mona Michael III 4
Accession 0001683168-18-000771
CIK 0001510964other
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 8:01 AM ET
Size
9.5 KB
Accession
0001683168-18-000771
Insider Transaction Report
Form 4
Mona Michael III
VP of Operations
Transactions
- Award
Employee Stock Option (right to buy)
2017-07-14+1,000,000→ 1,000,000 totalExercise: $0.37From: 2017-07-14Exp: 2026-07-05→ Common Stock (1,000,000 underlying) - Award
Employee Stock Option (right to buy)
2017-07-14+250,000→ 250,000 totalExercise: $0.36From: 2017-07-14Exp: 2027-04-06→ Common Stock (250,000 underlying)
Footnotes (3)
- [F1]On July 6, 2016, the Reporting Person was granted an option to purchase 4,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) the first time the Issuer completes development of a U.S. Food & Drug Administration ("FDA") current good manufacturing practice grade batch of successfully synthetically formulated Cannabidiol ("CBD") for use in drug development activities (25% vesting of the shares subject to the option); (ii) when the Company has final meeting minutes from a pre-investigational new drug application ("IND") meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (iii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iv) when the Company commences its first human dosing under the IND (25% vesting of the shares subject to the option).
- [F2]On July 14, 2017, the second performance criterion was met resulting in vesting of the option as to 1,000,000 shares.
- [F3]On April 7, 2017, the Reporting Person was granted an option to purchase 1,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) when the Company has final meeting minutes from a pre-IND meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (ii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iii) when the Company commences its first human dosing under the IND (50% vesting of the shares subject to the option). On July 14, 2017, the first performance criterion was met resulting in vesting of the option as to 250,000 shares.
Documents
Issuer
CV Sciences, Inc.
CIK 0001510964
Entity typeother
Related Parties
1- filerCIK 0001595068
Filing Metadata
- Form type
- 4
- Filed
- Mar 27, 8:00 PM ET
- Accepted
- Mar 28, 8:01 AM ET
- Size
- 9.5 KB